TriSTAR0703

TriSTAR0703 is a trispecific antibody being developed by Marengo Therapeutics for the treatment of various oncology indications. It is built upon the proprietary TriSTAR (Trispecific T Cell Engager) platform, which is designed to selectively activate and expand a specific pool of memory Vβ T cells. Unlike traditional T cell engagers that can lead to T cell exhaustion, the TriSTAR platform aims to redirect highly potent memory T cells to the tumor microenvironment, specifically targeting 'cold' tumors that are typically resistant to standard immunotherapies. TriSTAR0703 is currently a partnered program, although the specific molecular targets and the identity of the partner have not been publicly disclosed.